Recent Publications

Print

  • HOME
  • Recent Publications

Recent Publications

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013

Mashima, T., Iwasaki, R., Kawata, N., Kawakami, R., Kumagai, K., Migita, T., Sano, T., Yamaguchi, K. and Seimiya, H.
In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells.
Br. J. Cancer., in press (2019)
Udagawa, C., Horinouchi, H., Shiraishi, K., Kohno, T., Okusaka, T., Ueno, H., Tamura, K., Ohe, Y. and Zembutsu, H.
Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease.
PLoS One, in press (2019)
Hara-Nakano, M., Udagawa, C., Shimo, A., Kojima, Y., Yoshie, R., Zaha, H., Abe, N., Tokiwa, M., Uensoko, M., Tamura, K., Shimoi , T., Yoshida, M., Yoshida, T., Sakamoto, H., Kato, K., Mushiroda, T., Tsugawa, K. and Zembutsu, H.
A genome-wide association study identifies five novel genetic markers for trastuzumab-induced cardiotoxicity in Japanese population.
Biol. Pharm. Bull., in press (2019)
Katayama, R., Gong, B., Togashi, N., Miyamoto, M., Kiga, M., Iwasaki, S., Kamai, Y., Tominaga, Y., Takeda, Y., Kagoshima, Y., Shimizu, Y., Seto, Y., Oh-hara, T., Koike, S., Nakao, N., Hanazawa, H., Watanabe, K., Yoda, S., Yanagitani, N., Hata, A. N., Shaw, A. T., Nishio, M., Fujita, N. and Isoyama, T.
The new-generation selective ROS1/NTRK Inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
Nat. Commun., in press (2019)

ニュースリリース文章はこちら
Suzuki, Y., Kobayashi, K., Wakisaka, Y., Deng, D., Tanaka, S., Huang, C. J., Lei, C., Liu, H., Fujiwaki, Y., lee, S., isozaki, A., Kasai, Y., hayakawa, T., Sakuma, S., Arai, F., Koizumi, K., Tezuka, H., Inaba, M., hiraki, K., Ito, T., Hase, M., Matsusaka, S., Shiba, K., Suga, K., Nishikawa, M., Jona, M., Yatomi, Y., Yaxiaer, Y., Tanaka, Y., Sugimura, T., Nitta, N., Goda, K. and Yasuyuki, O.
Label-free chemical imaging flow cytometry by high-speed multicolor stimulated Raman scattering.
Proc. Natl. Acad. Sci. U. S. A., in press (2019)
Okada, K., Araki, M., Sakashita, T., Ma, B., Kanada, R., Yanagitani, N., Horiike, A., Koike, S., Oh-Hara, T., Watanabe, K., Tamai, K., Maemondo, M., Nishio, M., Ishikawa, T., Okuno, Y., Fujita, N. and Katayama, R.
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
EBioMedicine, 41, 105-119 (2019)
Gong, B., Kiyotani, K., Sakata, S., Nagano, S., Kumehara, S., Baba, S., Besse, B., Yanagitani, N., Friboulet, L., Nishio, M., Takeuchi, K., Kawamoto, H., Fujita, N. and Katayama, R.
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
J. Exp. Med., 216, 982-1000 (2019)
Suenaga, M., Wakatsuki, T., Mashima, T., Ogura, M., Ichimura, T., Shinozaki, E., nakayama, I., Osumi, H., Ota, Y., Takahari, D., Chin, K., Seimiya, H. and yamaguchi, K.
A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
Invest. New Drugs., in press (2019)
Matsumura, S., Minamisawa, T., Suga, K., Kishita, H., Akagi, T., Ichiki, T., Ichikawa, Y. and Shiba, K.
Subtypes of tumour cell-derived small extracellular vesicles having differently externalized phosphatidylserine.
J. Extracell. Vesicles, 8, (2019)
Osumi, H., Shinozaki, E., Yamaguchi, K. and Zembutsu, H.
Clinical utility of circulating tumor DNA for colorectal cancer.
Cancer Sci., in press (2019)

Return to Top of Page